HOPE™ Autism Products Launched in Australia as TGA Adds to Special Access Scheme

One of Zelira's top-performing medical product will soon reach the shores of Australia, fueling hope for many.

Zelira Therapeutics Ltd (ASX: ZLD) is pleased to announce that its proprietary cannabinoid medicines, HOPE 1™ and HOPE 2™, are now available by prescription to patients in Australia through the Therapeutic Goods Administration's (TGA) Special Access Scheme and via Authorised Prescribers. The HOPE™ range of products will be distributed nationally via Health House Holdings.

HOPE™ is part of Zelira's family of revenue-generating medicinal cannabis formulations. The products consist of two pharmaceutical-grade proprietary formulations developed as pharmaceutical-grade products targeting Autism Spectrum Disorder (ASD) as a disease indication.

The HOPE™ (HOPE 1 & 2) products were launched under license to Ilera Healthcare in Pennsylvania in 2019 with the support of HOPE Grows for Autism, a leading autism advocacy group based in Pennsylvania. HOPE™ has since established itself as one of the top-selling formulated medicinal cannabis products in Ilera Healthcare's portfolio. In August 2020, HOPE™ was launched under license in Louisiana in partnership with Advanced Biomedics LLC.

Following the success of the HOPE™ launches in Pennsylvania and Louisiana, we are excited to make these products available to patients and physicians in Australia Dr. Richard Hopkins, Managing Director

Dr Hopkins went on to say "This represents another key milestone in our commitment to bring the benefits of HOPE™ to patients in global markets. We believe HOPE™ can help support the unmet needs of the ASD community in Australia and look forward to working with all stakeholders to ensure they can access the benefits that medicinal cannabis can provide."

For the latest news and updates on Zelira Therapeutics, click here

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Mark Page
Mark Page

Mark is a UK born investing enthusiast based in Sydney. He has a keen eye for technical analysis and is paying close attention to the ongoing legalisation of cannabis for the health benefits, opportunities, and emergent industries that will follow.

Leave a Reply

Your email address will not be published. Required fields are marked *